256 related articles for article (PubMed ID: 10982299)
1. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
2. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
Prayson RA
Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 in oligodendroglial neoplasms.
Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
[TBL] [Abstract][Full Text] [Related]
4. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
6. Oligodendroglioma: does deferring treatment compromise outcome?
Feigenberg SJ; Amdur RJ; Morris CG; Mendenhall WM; Marcus RB; Friedman WA
Am J Clin Oncol; 2003 Jun; 26(3):e60-6. PubMed ID: 12796617
[TBL] [Abstract][Full Text] [Related]
7. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
8. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic xanthoastrocytoma: what do we really know about it?
Giannini C; Scheithauer BW; Burger PC; Brat DJ; Wollan PC; Lach B; O'Neill BP
Cancer; 1999 May; 85(9):2033-45. PubMed ID: 10223246
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
11. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
Fanburg-Smith JC; Furlong MA; Childers EL
Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of malignant features in oligodendroglial tumors.
Saito A; Nakazato Y
Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
[TBL] [Abstract][Full Text] [Related]
13. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas.
Broholm H; Bols B; Heegaard S; Braendstrup O
Clin Neuropathol; 1999; 18(4):176-80. PubMed ID: 10442459
[TBL] [Abstract][Full Text] [Related]
15. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
[TBL] [Abstract][Full Text] [Related]
16. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
17. [Primary retroperitoneal tumors. Treatment modality and prognostic factors].
Boneschi M; Erba M; Cusmai F; Eusebio D; Miani S; Bortolani EM
Minerva Chir; 1999 Nov; 54(11):763-8. PubMed ID: 10638149
[TBL] [Abstract][Full Text] [Related]
18. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
19. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.
Luyken C; Blümcke I; Fimmers R; Urbach H; Wiestler OD; Schramm J
Cancer; 2004 Jul; 101(1):146-55. PubMed ID: 15222000
[TBL] [Abstract][Full Text] [Related]
20. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
